24.1 C
Basseterre
Wednesday, December 7, 2022
HomeNewsInternational NewsPfizer Ends COVID-19 Trial With 95% Efficacy, To Seek Emergency-Use Authorization

Pfizer Ends COVID-19 Trial With 95% Efficacy, To Seek Emergency-Use Authorization

spot_img

(Reuters) – Pfizer Inc PFE.N said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

The drugmaker said the efficacy of the vaccine developed with German partner BioNTech SE BNTX.O22UAy.F was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.

Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%.

The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.

Moderna Inc MRNA.O on Monday released preliminary data for its vaccine, showing similar effectiveness.

Read more

MAKANA FERRY SCHEDULE

spot_img
spot_img
spot_img

Most Popular

spot_img
Advertisement
Contact a Program
If you are interested in a program or advertising, send us a message.
Send Message
Signup for our Newsletter
We'll only be in touch when we've something exciting to share.
We never share your details
No thanks
Subscribe